瑞米布替尼(Remibrutinib) - 药物靶点：BTK_在研适应症：慢性荨麻疹，重症肌无力，化脓性汗腺炎_专利_临床

概要

基本信息

药物类型

小分子化药

别名

LOU 064、LOU-064、LOU064

+ [1]

靶点

BTK

作用方式

抑制剂

作用机制

BTK抑制剂(酪氨酸蛋白激酶BTK抑制剂)

治疗领域

肿瘤免疫系统疾病神经系统疾病+ [4]

在研适应症

慢性荨麻疹重症肌无力化脓性汗腺炎+ [4]

非在研适应症

哮喘特应性皮炎干燥综合征

原研机构

Novartis Pharma AG

在研机构

Novartis Pharmaceuticals Corp.诺华（中国）生物医学研究有限公司

Novartis Pharmaceuticals Canada, Inc.

+ [4]

非在研机构

Novartis Pharma AG

权益机构-

最高研发阶段申请上市

首次获批日期-

最高研发阶段(中国)申请上市

特殊审评优先审评 (中国)

登录后查看时间轴

结构/序列

分子式C27H27F2N5O3

InChIKeyCUABMPOJOBCXJI-UHFFFAOYSA-N

CAS号1787294-07-8

关联

32

项与瑞米布替尼相关的临床试验

NCT06868212

/ Recruiting临床3期

A US Phase 3b, Multi-center, Randomized, Double-blind, Double-Dummy Study to Evaluate Efficacy of Remibrutinib Compared to Dupilumab at Early Timepoints in Adults With Chronic Spontaneous Urticaria Inadequately Controlled by Second Generation H1-Antihistamines

This is a US, multi-center, randomized, double-blind, double-dummy, Phase 3b study to evaluate efficacy of remibrutinib (25 mg twice daily [b.i.d.] by mouth [p.o.]) compared to dupilumab (600 mg loading dose administered subcutaneously (s.c.) followed by 300 mg every 2 weeks s.c.) at early timepoints (4 weeks and earlier), when administered as an add-on treatment to second generation H1-antihistamines (sgH1-AH) (standard label dose as background therapy) in adult US participants with moderate to severe chronic spontaneous urticaria (CSU) inadequately controlled by sgH1-AHs.

开始日期2025-07-25

申办/合作机构

Novartis Pharmaceuticals Canada, Inc.

NCT07032272

/ Not yet recruiting临床1期

A Phase 1, Open-label Study to Investigate the Pharmacokinetics and Safety of Remibrutinib (LOU064) in Participants With Severe Renal Impairment Compared to Matched Healthy Participants With Normal Renal Function

The purpose of this study is to support the development of remibrutinib dosing recommendations for patients with impaired renal function.

开始日期2025-06-27

申办/合作机构

Novartis Pharmaceuticals Canada, Inc.

NCT06846281

/ Not yet recruiting临床3期

A Randomized, Open-label, Parallel-group, Non-inferiority Study Comparing Efficacy, Safety, and Tolerability of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis, Followed by Open-label Treatment With Remibrutinib

The purpose of this Phase 3b study is to assess the efficacy, safety and tolerability of remibrutinib after switching from ocrelizumab and compared to continuous ocrelizumab treatment, in patients living with relapsing multiple sclerosis (plwRMS).

开始日期2025-06-16

申办/合作机构

Novartis Pharmaceuticals Canada, Inc.

100 项与瑞米布替尼相关的临床结果

登录后查看更多信息

100 项与瑞米布替尼相关的转化医学

登录后查看更多信息

100 项与瑞米布替尼相关的专利（医药）

登录后查看更多信息

45

项与瑞米布替尼相关的文献（医药）

2025-09-01·EUROPEAN JOURNAL OF PHARMACOLOGY

Next generation Bruton's tyrosine kinase inhibitors – characterization of in vitro potency and selectivity

Article

作者: Angst, Daniela ; Cenni, Bruno ; Pulz, Robert

Bruton's tyrosine kinase (BTK) mediates B cell receptor and Fc receptor signaling and is a key regulator of autoimmunity and allergy. A series of novel BTK inhibitors (BTKi) are currently in development for non-oncologic indications with covalent-irreversible (remibrutinib, evobrutinib, tolebrutinib, orelabrutinib), covalent-reversible (rilzabrutinib), and non-covalent reversible (fenebrutinib) binding modes. This study characterizes their in vitro potency and selectivity profiles under the same conditions to minimize assay differences across the different binding modes. Covalent BTKi showed human in vitro blood BTK binding in a time- and concentration-dependent manner with remibrutinib being the most potent and fastest in onset of action. Cellular BTK pathway inhibition was determined in human blood B cells and basophils, and for covalent BTKi correlated well with BTK binding. In contrast to the covalent-irreversible remibrutinib, the non-covalent reversible fenebrutinib showed rapid loss of cellular BTK inhibition after washout. Kinase selectivity was assessed in a binding screen across the human kinome, followed by quantification of binding affinities for a selection of kinases. BTKi ranked in their selectivity as follows (most selective to least): remibrutinib, fenebrutinib, evobrutinib, orelabrutinib, rilzabrutinib and tolebrutinib. These data suggest that next generation BTKi show important differences in their in vitro target binding and selectivity when compared under the same conditions.

2025-07-18·ALLERGY

Efficacy of Omalizumab, Dupilumab, and Remibrutinib in Chronic Spontaneous Urticaria: Phase Data and Placebo Response.

Letter

作者: Yılmaz, İnsu ; Kocatürk, Emek ; Türk, Murat ; Ertaş, Ragıp

2025-07-01·JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

Comparative efficacy and safety of biologics and systemic immunomodulatory treatments for chronic urticaria: Systematic review and network meta-analysis

Article

作者: Dam, Andrew ; Chu, Xiajing ; Mathur, Sameer K ; Flindall, Maisie ; Moellman, Joseph ; Baker, Diane R ; Saini, Sarbjit S ; Cole, Emily F ; Gardner, Donna D ; Sheikh, Javed ; Waserman, Susan ; Winders, Tonya ; Lang, David M ; Tattrie, Jamie ; Chu, Derek K ; Trayes, Kathryn P ; Oykhman, Paul ; Bernstein, Jonathan A ; Chan, Jeffrey ; Asiniwasis, Rachel N ; Runyon, Lauren ; Ben-Shoshan, Moshe ; Khan, David A ; Beck, Lisa A ; Eftekhari, Sanaz ; Bhangal, Sukhdeep ; Frazier, Winfred T ; Chu, Alexandro W L ; Wheeler, Kathryn E ; Xu, Janice ; Thabane, Lehana ; Oliver, Eric T ; Rayner, Daniel G

BACKGROUND:

Chronic urticaria is a common skin condition characterized by itchy wheals (hives), angioedema, or both, lasting for 6 weeks or more. Beyond antihistamines, multiple systemic treatments are available, but there is uncertainty regarding their comparative effects on chronic urticaria outcomes.

OBJECTIVE:

We systematically synthesized the comparative benefits and harms of systemic treatments for chronic urticaria.

METHODS:

As part of updating the AAAAI/ACAAI JTFPP chronic urticaria guidelines, we searched Medline, Embase, Central, Chinese Biomedical Databases (CBM), China National Knowledge Infrastructure (CNKI), Chinese Scientific Journal Database (VIP), and Wanfang from inception to February 4, 2025, for randomized trials addressing systemic immunomodulatory treatments, including phototherapy, for chronic urticaria. Paired reviewers screened records, extracted data, and assessed risk of bias. Random effects Bayesian network meta-analyses addressed urticaria activity (comprising itch and wheal scores), angioedema activity, health-related quality of life, and adverse events. The GRADE approach informed certainty-of-evidence ratings (PROSPERO: CRD42023429819).

RESULTS:

We included 93 studies (n = 11,398; mostly adult and adolescent participants across 83 randomized trials and 10 nonrandomized studies) that evaluated 42 interventions. With high certainty, standard-dose omalizumab (300 mg every 4 weeks) and remibrutinib are among the most effective for improving multiple patient-important outcomes. The safety profile of remibrutinib, however, is less certain. Dupilumab improved urticaria activity, but its impact on quality of life is uncertain, and no dupilumab trials addressed angioedema activity. Cyclosporine may be among the most effective for improving urticaria activity but may be among the most harmful in increasing the frequency of any adverse events. Azathioprine, dapsone, hydroxychloroquine, mycophenolate, sulfasalazine, and vitamin D may improve outcomes, while benralizumab, quilizumab, and tezepelumab may not differ from placebo, though the evidence is uncertain. Findings were consistent across age groups and baseline severity, and were robust to subgroup analyses.

CONCLUSIONS:

Among individuals with chronic urticaria refractory to antihistamines, standard-dose omalizumab and remibrutinib are among the most effective drugs across multiple patient-important outcomes with a favorable safety profile across the studied duration. Cyclosporine may be effective but may be among the most harmful. Dupilumab improves itch and wheals, but it is uncertain whether it improves angioedema or quality of life. Lower doses of omalizumab are of intermediate effectiveness and favorable safety. The net benefit of conventional immunosuppressants is uncertain.

157

项与瑞米布替尼相关的新闻（医药）

2025-07-22

·医药地理

诺华2025H1财报：双位数增长背后，创新药成关键引擎

2025年的钟声刚刚过半，诺华便以一份“超速”财报震撼全球医药市场：营收与利润双位数跃升，核心创新药管线全面点火，资本回报计划再度加码。这不仅是一组亮眼的数字，更是一张清晰的战略答卷——在专利悬崖与竞争红海并存的时代，诺华正以创新驱动高增长，用真金白银回馈投资者，向世界宣告：大象不仅能跳舞，还能加速奔跑。诺华首席执行官万思瀚（Vas Narasimhan）在评论2025年第二季度业绩时表示：”诺华第二季度业绩再度表现强劲，净销售额和核心营业收入均实现双位数增长。Kisqali（凯丽隆®）、Pluvicto（暂未在中国上市）和Scemblix（信倍立®）等新药及新适应症上市后表现出色，彰显了我们在产品组合方面的更新迭代能力。本季度我们在未来产品线方面也取得了重要进展，包括Pluvicto用于PSMA阳性转移性激素敏感性前列腺癌的III期研究获得第三项积极结果，以及启动OAV101 IT用于脊髓性肌萎缩症的全球注册申请。凭借稳健的资产负债表和对中长期增长的信心，我们决定启动最高达100亿美元的股票回购计划，以履行我们对均衡资本配置的承诺。”一、核心速览：业绩“超预期”，全年指引再上调在2025年第二季度，诺华再次展现了其强劲的财务表现，实现了双位数的销售增长和核心运营收入的增长。净销售额达到了140.5亿美元，同比增长12%，而核心营业收入则上升至59.25亿美元，同比增长20%。尤为值得一提的是，核心运营利润率达到了42.2%，同比增加340个基点。在2025上半年，诺华净销售额达到了272.87亿美元，同比增长12%，核心营业收入115亿元，同比增长21%，其中中国区净销售额22亿美元，同比增长8%。基于如此亮眼的表现，诺华上调了其2025财年的核心运营收入指引，预计销售额将实现高个位数增长，并且核心运营收入将以低两位数的速度增长。图1 财务摘要来源：诺华2025Q2财报二、增长引擎拆解：六大“火箭单品”齐发诺华的持续增长得益于几款明星产品的突出表现，这包括Kisqali（凯丽隆®）、Entresto（诺欣妥®）、Kesimpta（全欣达®）、Scemblix（信倍立®）、Leqvio（乐可为®）以及Pluvicto等六大“火箭单品”。在二季度，Kisqali（凯丽隆®）凭借在美国市场新推出的早期乳腺癌适应症及转移性乳腺癌市场份额的增加，达到了11.77亿美元的销售额，同比增长64%。Entresto（诺欣妥®）在心血管领域的需求推动下，销售额达到23.57亿美元，同比增长22%。作为全球首款血管紧张素受体脑啡肽酶抑制剂（ARNI），此款药物近年来在中国市场销售表现强劲，自2017年在中国获批心衰适应症、2021年获批高血压适应症后，销售额持续攀升，2024年院端销售额增至约38亿元（如图2），成为心血管领域的重磅产品，近期因专利侵高风险未被纳入第十一批集采目录。全球唯一为多发性硬化患者定制的全人源CD20单抗Kesimpta（全欣达®）在需求增长和市场准入强劲的推动下，销售额也突破10亿美元，同比增长33%。此外，Scemblix（信倍立®）在慢性髓细胞白血病治疗中的应用也取得了显著进展，销售额达2.98亿美元，同比激增79%。全球首创小干扰RNA降胆固醇药物Leqvio（乐可为®）以2.98亿美元的销售额实现61%的稳步增长。用于更早线未经化疗的PSMA阳性的转移性去势抵抗性前列腺癌的Pluvicto销售额达4.54亿美元，同比增长30%。这些产品的成功不仅证明了诺华在其核心治疗领域的强大竞争力，也为未来的增长奠定了坚实的基础。图2 Entresto（诺欣妥®）国内院端放大市场金额（2020-2024）数据来源：PDB药物综合数据库图3 明星产品汇总来源：诺华2025Q2财报三、研发里程碑：从“单点突破”到“平台势能”诺华的研发管线同样取得了多项重要里程碑。例如，Pluvicto在PSMA阳性转移性激素敏感前列腺癌患者中的三期临床试验取得了积极结果，显示出了统计学意义和临床意义的放射学无进展生存期改善；Vanrafia获得了FDA加速批准用于成人原发性免疫球蛋白A肾病患者的治疗；OAV101 IT在美国和欧盟提交了用于脊髓性肌萎缩症的注册申请；Votoplam用于亨廷顿病的Ⅱ期PIVOT-HD研究以及Remibrutinib用于食物过敏的Ⅱ期研究取得积极结果，这进一步巩固了诺华在创新药物开发方面的领导地位。同时，诺华正在通过基因与细胞疗法、放射配体疗法和xRNA等新兴平台的投资，推动从单一产品突破向整体平台能力提升的战略转型，旨在利用这些技术解决高疾病负担并拥有巨大增长潜力的领域。这些努力不仅再次印证了诺华作为一家“pure-play”innovative medicines company的战略决心，也为公司下一阶段的新药输出奠定了可验证、可持续、可扩张的坚实底座。图4 研发管线进展来源：诺华2025Q2财报结语当市场还在争论“后专利时代”的增长极限时，诺华已经用2025上半年的数据给出答案：创新不是选择题，而是必答题。从六款“火箭单品”的集体升空，到Pluvicto、OAV101 IT叩响的新适应症大门，再到100亿美元回购所释放的现金流自信，诺华把“研发-上市-回报”的闭环跑成了螺旋上升的飞轮。这再次提醒市场，真正的护城河不是专利，而是把创新写进基因、把患者需求刻进每一次心跳。故事至此，不是终章，只是序曲，因为只要疾病未被根除，探索就不会停笔，而诺华已把笔递给了未来。END如需获取更多数据洞察信息或公众号内容合作，请联系医药地理小助手微信号：pharmadl001

2025-07-18

·药事纵横

诺华2025年Q2业绩快报分析：业绩增长强劲，未来可期

7月17日，诺华公司公布了2025年Q2的业绩快报，内容总结如下：一、核心财务表现：双位数增长的全面胜利‌营收‌：Q2净销售额达140.5亿美元（同比增长12%，按固定汇率计算+11%），上半年累计272.9亿美元（+13% cc）。增长主要由核心产品驱动，其中Kisqali（乳腺癌药物）销售额飙升64%，Entresto（心衰药）增长22%，Pluvicto（前列腺癌疗法）增长30%。‌利润率提升‌：核心营业利润率达42.2%，同比提升340个基点，反映产品组合优化与运营效率改进。‌现金流‌：Q2自由现金流63亿美元（+37%），为战略布局提供充足弹药。CEO Vas Narasimhan特别强调："我们的在研管线转化能力持续释放，Pluvicto、Kisqali等产品的商业化成功证明了创新管线的替代力。"诺华主要产品销售表现二、明星产品矩阵：多领域开花结果诺华的"四核治疗领域"战略（心血管-代谢、免疫、神经科学、肿瘤）成效显著：‌肿瘤领域‌Kisqali：早期乳腺癌适应症推动美国市场增长超100%Pluvicto：前列腺癌III期研究PSMAddition达主要终点，将提交监管审批Scemblix（白血病药）：销售额同比暴涨79%‌心血管与代谢‌Entresto：全球需求稳健，22%增长Leqvio（降脂药）：患者采纳率提升推动61%增长‌新兴技术平台‌基因疗法OAV101完成欧美申报，放射配体疗法Pluvicto三期数据亮眼，验证了诺华在xRNA、放射性药物等前沿领域的布局。三、研发里程碑：未来增长引擎加速Q2研发管线取得多项突破：‌重磅审批‌：Vanrafia（IgA肾病药）获FDA加速批准，Coartem Baby（疟疾药）获瑞士批准‌临床突破‌亨廷顿病药物Votoplam II期达主要终点食物过敏药remibrutinib II期结果积极‌战略收购‌：完成对Regulus Therapeutics（microRNA疗法）的收购，强化肾病管线四、资本运作与2025展望诺华展现出强大的资本管理能力：‌股票回购‌：启动高达100亿美元的股票回购计划（2027年底前完成）‌股息政策‌：上半年支付股息78亿美元‌财务指引上调‌：将2025年核心营业利润增长预期从"低双位数"提升至"低十位数"风险提示包括Entresto美国仿制药可能于年中上市，但管理层对中长期增长保持信心。五、战略聚焦：纯创新药企的进阶之路诺华的三大战略支柱清晰可见：‌加速增长‌：聚焦高价值新分子实体（NMEs），目前80%在研管线属于潜在"重磅炸弹"‌技术平台深化‌：重点发展基因治疗、放射配体、xRNA三大新兴平台‌地域扩张‌：美国、中国、德国、日本四大市场贡献超60%营收‌结语‌诺华Q2业绩印证了其向"纯创新药企"转型的成功。通过核心产品放量、管线高效转化和严谨的资本配置，公司不仅实现短期财务目标，更为长期增长奠定基础。随着Pluvicto等新一代疗法陆续上市，以及基因编辑等前沿技术的持续投入，诺华有望在未来五年保持行业领先地位。药事纵横投稿须知：稿费已上调，欢迎投稿

财报临床3期基因疗法放射疗法引进/卖出

2025-07-17

·FierceBiotech

Novartis\' B-cell-depleting antibody fails to show promise in phase 2 dermatology study

\"All other studies for ianalumab in B-cell driven diseases continue as planned,” Novartis said.\n Novartis has ended work on ianalumab in a painful skin condition after the monoclonal antibody failed to meet “predefined efficacy thresholds” in a phase 2 study.The Swiss pharma had been evaluating ianalumab, a dual-mechanism, B-cell-depleting antibody that targets the protein BAFF-R, in a midstage study of hidradenitis suppurativa—a skin disease that causes painful lumps to form in areas where the skin rubs together. The company already markets Cosentyx for the skin condition.In its second-quarter earnings results, Novartis revealed that it will now stop development of ianalumab in this indication after the phase 2 trial “did not meet our target criteria despite demonstrating efficacy versus placebo.”“No new safety signals were observed and all other studies for ianalumab in B-cell driven diseases continue as planned,” the drugmaker added.Novartis is still, however, lining up the drug for an approval application next year in Sjögren’s disease, an immune disorder that causes dry eyes and a dry mouth. At the start of the year, the company abandoned attempts to develop its anti-CD40 antibody iscalimab for the same disorder.At the time, Novartis’ chief medical officer and head of development Shreeram Aradhye, M.D., pointed out to Fierce Biotech that ianalumab had already “shown meaningful differences in patients with this very difficult to treat disease” in a phase 2 trial. A pair of phase 3 trials for ianalumab in Sjögren’s disease are due to read out in the second half of this year, along with a late-stage study in second-line immune thrombocytopenia.Despite not pursuing ianalumab in hidradenitis suppurativa, Novartis still has another pipeline option for the skin condition in the form of remibrutinib. The BTK inhibitor was shown to reduce disease activity in a phase 2b trial last year and is currently being studied in pair of phase 3 trials due to read out in 2028.

$Novartis\' B-cell-depleting antibody fails to show promise in phase 2 dermatology study$

临床2期临床3期免疫疗法

100 项与瑞米布替尼相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
慢性荨麻疹	申请上市	中国	北京诺华制药有限公司	2025-02-27
慢性荨麻疹	申请上市	中国	Novartis Pharma Schweiz AG	2025-02-27
慢性荨麻疹	申请上市	中国	Novartis Pharmaceutical Manufacturing GmbH	2025-02-27
重症肌无力	临床3期	美国	诺华（中国）生物医学研究有限公司	2025-02-07
重症肌无力	临床3期	美国	Novartis Pharmaceuticals Canada, Inc.	2025-02-07
重症肌无力	临床3期	中国	诺华（中国）生物医学研究有限公司	2025-02-07
重症肌无力	临床3期	日本	诺华（中国）生物医学研究有限公司	2025-02-07
重症肌无力	临床3期	日本	Novartis Pharmaceuticals Canada, Inc.	2025-02-07
重症肌无力	临床3期	阿根廷	诺华（中国）生物医学研究有限公司	2025-02-07
重症肌无力	临床3期	澳大利亚	诺华（中国）生物医学研究有限公司	2025-02-07

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT05795153 (CTgov)	临床3期	慢性荨麻疹	144	LOU064	網齋網積襯壓鹹製淵夢(餘襯製窪襯鑰鹽鹽簾餘) = 簾餘齋觸願簾願壓壓積憲獵齋鹹鏇網獵築鏇繭 (鬱膚製鬱網艱鑰鏇襯獵, 鑰鏇積廠廠糧獵襯膚鏇 ~ 鏇積鑰簾觸醖艱鹹選淵) 更多	-	2025-04-30
NCT05032157 \| NCT05030311 (REMIX-2, NEWS \| Pubmed) 人工标引	临床3期	荨麻疹	-	remibrutinib (REMIX-1)	簾艱構廠窪構廠願製獵(艱鑰憲憲顧憲觸積築鬱) = 構窪簾糧積襯遞網獵網簾積鏇願鏇壓鹽範鏇遞 (構選鹹淵選積製糧齋觸, 0.7) 更多	积极	2025-03-11
				placebo (REMIX-1)	簾艱構廠窪構廠願製獵(艱鑰憲憲顧憲觸積築鬱) = 糧膚繭鬱鹽餘衊廠膚遞簾積鏇願鏇壓鹽範鏇遞 (構選鹹淵選積製糧齋觸, 1.0) 更多
REMIX-1 and REMIX-2 (Pubmed \| N Engl J Med)	临床3期	慢性荨麻疹 Bruton's tyrosine kinase	-	Remibrutinib 25 mg twice daily	鏇廠膚窪蓋築餘鏇膚繭(獵觸範膚襯築遞遞簾構) = 糧鑰醖選築鏇繭鬱遞齋築繭窪鹹糧顧鏇積構糧 (鏇艱廠糧窪製淵願製簾 ) 更多	积极	2025-03-06
				Placebo	鏇廠膚窪蓋築餘鏇膚繭(獵觸範膚襯築遞遞簾構) = 憲廠繭夢鏇觸顧遞淵鑰築繭窪鹹糧顧鏇積構糧 (鏇艱廠糧窪製淵願製簾 ) 更多
NCT05030311 (REMIX-1, CTgov)	临床3期	慢性荨麻疹	470	LOU064 (LOU064 25mg b.i.d.)	壓顧積壓衊夢構鑰襯顧(選範積鑰夢艱鏇築窪淵) = 積壓淵廠鑰鏇鏇選憲積夢襯網壓醖觸繭獵築淵 (鏇膚鏇壓膚繭蓋願顧鹹, 0.716) 更多	-	2024-12-02
				Placebo+LOU064 (Placebo)	壓顧積壓衊夢構鑰襯顧(選範積鑰夢艱鏇築窪淵) = 鑰願鹽淵鏇顧窪鬱糧齋夢襯網壓醖觸繭獵築淵 (鏇膚鏇壓膚繭蓋願顧鹹, 0.980) 更多
NCT05048342 (BISCUIT, CTgov)	临床3期	慢性荨麻疹	71	LOU064	壓鑰簾窪鹹繭廠構鹹選 = 窪淵網觸製鏇廠糧艱餘衊遞夢鹽築築觸構窪構 (窪糧襯遞衊遞顧簾鑰餘, 製鬱餘範衊願鏇製夢鑰 ~ 鏇鑰憲壓積壓醖鏇遞襯) 更多	-	2024-11-22
NCT05032157 (REMIX-2, CTgov)	临床3期	慢性荨麻疹	455	LOU064 (open-label)+Placebo	艱獵願糧蓋蓋淵餘積選(醖蓋淵顧餘艱鏇願構鑰) = 願齋淵鹹蓋窪蓋醖獵獵艱膚構壓憲齋顧鏇繭願 (壓夢糧網選築簾衊艱選, 0.948) 更多	-	2024-11-01
REMIX-1/-2 (ACAAI2024)	临床3期	慢性荨麻疹 Bruton's tyrosine kinase (BTK)	-	Remibrutinib 25 mg twice daily	積築構鹹願艱觸餘鬱鬱(築糧簾構鏇壓遞衊顧蓋) = 糧淵廠築構窪獵鑰選繭糧壓窪製窪夢膚願艱餘 (蓋鹹選壓鹽網顧鏇醖顧 ) 更多	积极	2024-10-24
NCT03926611 (Phase 2b core and extension study, EAN2024)	临床2期	血清病	309	Remibrutinib 100 mg b.i.d.	顧構鹽窪窪築簾衊製糧(鑰壓壓獵構構糧獵積淵) = 糧衊願淵製遞製衊鹽鹽壓鹽壓齋鬱繭夢鬱築網 (膚鑰餘壓鬱鬱製繭構憲, 2.47) 更多	积极	2024-06-28
NCT05032157 (REMIX-2, GlobeNewswire) 人工标引	临床3期	慢性荨麻疹	455	Remibrutinib	艱獵製蓋鹽鹽窪蓋窪艱(網鬱築鹽範鹽鏇遞繭鑰) = Almost half of patients were completely free of itch and hives (UAS7=0) as assessed at Week 52 衊簾齋餘製壓齋艱範憲 (壓鹹製襯膚顧蓋夢醖鬱 ) 更多	积极	2024-05-30
				Placebo
NCT05030311 (REMIX-1, GlobeNewswire) 人工标引	临床3期	慢性荨麻疹	470	Remibrutinib	廠糧鏇餘選鑰壓壓襯窪(製艱選簾廠選窪淵鹹衊) = Almost half of patients were completely free of itch and hives (UAS7=0) as assessed at Week 52 鑰膚鹹艱鏇獵廠積糧積 (鹽繭願鑰鏇選獵淵衊夢 ) 更多	积极	2024-05-30
				Placebo